Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008

D. E. Furst, E. C. Keystone, B. Kirkham, R. Fleischmann, P. Mease, F. C. Breedveld, J. S. Smolen, J. R. Kalden, G. R. Burmester, J. Braun, P. Emery, K. Winthrop, B. Bresnihan, F. De Benedetti, T. Dörner, A. Gibofsky, M. H. Schiff, J. Sieper, N. Singer, P. L C M Van RielM. E. Weinblatt, M. H. Weisman

Research output: Contribution to journalArticlepeer-review

Abstract

Rituximab is effective in patients with an inadequate response to MTX for whom conventional DMARDS have failed or have one or more TNFα blocking agents. The safety of rituximab is still being defined. It is hoped that this statement, based on the best evidence available at this time, and modified by expert opinion, will facilitate the optimal use of these agents.

Original languageEnglish
JournalAnnals of the Rheumatic Diseases
Volume67
Issue numberSUPPL. 3
DOIs
Publication statusPublished - Dec 2008

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Allergy

Fingerprint Dive into the research topics of 'Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008'. Together they form a unique fingerprint.

Cite this